A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 377 participants.
Also called NCT02271217
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 377 participants
- Sponsor
- Acorda Therapeutics
- Registry
-
NCT02271217
-
- Other papers using this trial's data
- A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02271217. Randomized; quadruple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2017-12-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
- Acronym
- MILESTONE℠
- Condition
- Post-Ischemic Stroke
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- dalfampridine-ER 7.5mg
- Intervention (Drug)
- dalfampridine-ER 10mg
- Lead sponsor
- Acorda Therapeutics
Record details
- Record id
cardio:ct-nct02271217- Content hash
7d0989282b82b13ef31bcf531b5f35ce69aca176d053b1ce9a6a0ddd09a7c814